» Articles » PMID: 39277863

Butyrate and Propionate Are Microbial Danger Signals That Activate the NLRP3 Inflammasome in Human Macrophages Upon TLR Stimulation

Abstract

Short-chain fatty acids (SCFAs) are immunomodulatory compounds produced by the microbiome through dietary fiber fermentation. Although generally considered beneficial for gut health, patients suffering from inflammatory bowel disease (IBD) display poor tolerance to fiber-rich diets, suggesting that SCFAs may have contrary effects under inflammatory conditions. To investigate this, we examined the effect of SCFAs on human macrophages in the presence of Toll-like receptor (TLR) agonists. In contrast to anti-inflammatory effects under steady-state conditions, we found that butyrate and propionate activated the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome in the presence of TLR agonists. Mechanistically, these SCFAs prevented transcription of FLICE-like inhibitory protein (cFLIP) and interleukin-10 (IL-10) through histone deacetylase (HDAC) inhibition, triggering caspase-8-dependent NLRP3 inflammasome activation. SCFA-driven NLRP3 activation was potassium efflux independent and did not result in cell death but rather triggered hyperactivation and IL-1β release. Our findings demonstrate that butyrate and propionate are bacterially derived danger signals that regulate NLRP3 inflammasome activation through epigenetic modulation of the inflammatory response.

Citing Articles

Gut microbiota in treating inflammatory digestive diseases: Current challenges and therapeutic opportunities.

Shi Y, Chen Z, Fang T, Chen X, Deng Y, Qin H Imeta. 2025; 4(1):e265.

PMID: 40027479 PMC: 11865350. DOI: 10.1002/imt2.265.


Towards Improved Bioavailability of Cereal Inositol Phosphates, -Inositol and Phenolic Acids.

Zyla K, Duda A Molecules. 2025; 30(3).

PMID: 39942756 PMC: 11820786. DOI: 10.3390/molecules30030652.


Gut microbiota and inflammasome-mediated pyroptosis: a bibliometric analysis from 2014 to 2023.

Zhang H, Zhao T, Gu J, Tang F, Zhu L Front Microbiol. 2025; 15():1413490.

PMID: 39834371 PMC: 11743621. DOI: 10.3389/fmicb.2024.1413490.


Recent advances in gut microbiota and thyroid disease: pathogenesis and therapeutics in autoimmune, neoplastic, and nodular conditions.

Fang L, Ning J Front Cell Infect Microbiol. 2025; 14():1465928.

PMID: 39776440 PMC: 11703873. DOI: 10.3389/fcimb.2024.1465928.


Pyroptosis the Emerging Link Between Gut Microbiota and Multiple Sclerosis.

Fan H, Shen R, Yan J, Bai Y, Fu Q, Shi X Drug Des Devel Ther. 2024; 18:6145-6164.

PMID: 39717200 PMC: 11665440. DOI: 10.2147/DDDT.S489454.